Super-Sized Life Science Investments, Healthy Returns?
This article was originally published in Start Up
Intarcia Therapeutics just raised $210 million in equity and debt to support Phase III trials of its implantable version of the diabetes drug exenatide. What eventually happens to life science companies that reel in massive rounds of funding? We examine the top 25.